Checking in on the levels: Where are Canada’s PSPs today?
January 23, 2020
Two years ago, 20Sense published an infographic describing four levels of PSP.18 Since that time, manufacturers have redoubled their efforts to reach levels 3 and 4. In collaboration with payers, patients and PSP providers, they are exploring opportunities to generate actionable data from their PSPs, including data to support outcomes-based reimbursement agreements.19 Patient data generated by PSPs—such as disease scores, safety, and adherence patterns—yields unparalleled insights into a treatment’s value, enabling stakeholders to make informed decisions about treatment, reimbursement and strategy.20
Basic PSP programs work well. Advancing through the levels makes them work even better. Higher-level PSPs yield a greater ROI and, above all, greater value to patients.
References:
18 - Optimize Your Operations: Take your PSP to the Next Level. 20Sense, January 15, 2018. https://www.20sense.ca/issue-2-biosimilars-and-patient-support-a-musthave-combination/2018/1/15/biosimilars-and-patient-support-a-must-have-combination-kf3s2
19 - RWE and OBA Working Group. 2019 Research and Outputs. November 25, 2019. https://static1.squarespace.com/static/58fd16af1b631b1afffae9e0/t/5dd9fd27b53adb35ea83ac32/1574567208259/2019_RWE_OBA_WorkingGroup_ExecSummary.pdf
20 - Insight Series: Value of Patient Support Programs for Specialty Medications in Canada. Innomar Strategies. May 17, 2018. https://www.innomar-strategies.com/insights/insight-series-value-of-patient-support-programs